Reuters logo
Xenon Pharmaceuticals' acne drug fails mid-stage study
2017年3月24日 / 上午10点45分 / 6 个月前

Xenon Pharmaceuticals' acne drug fails mid-stage study

March 24 (Reuters) - Xenon Pharmaceuticals Inc said on Friday its drug to treat moderate to severe facial acne failed to meet the primary goal in a mid-stage study.

The drug, XEN801, which was tested against a placebo, did not induce a statistically significant effect on total lesion count, the company said. (Reporting by Divya Grover in Bengaluru; Editing by Martina D‘Couto)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below